How should sodium‑glucose cotransporter‑2 (SGLT2) inhibitors be used in adult patients with chronic heart failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

SGLT2 Inhibitors in Heart Failure: Clinical Implementation

SGLT2 inhibitors (dapagliflozin or empagliflozin) should be prescribed to all patients with heart failure and reduced ejection fraction (LVEF ≤40%), regardless of diabetes status, to reduce cardiovascular mortality and heart failure hospitalizations. 1

Core Recommendations by Heart Failure Type

Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF ≤40%)

Strong recommendation for SGLT2 inhibitor use 1, 2:

  • Dapagliflozin 10 mg daily or empagliflozin 10 mg daily
  • Benefits: 16% reduction in all-cause/CV mortality, 31% reduction in HF hospitalization, 41% reduction in composite kidney outcomes 3
  • Use in all patients with or without diabetes
  • Start early in disease course—do not wait for maximally tolerated guideline-directed medical therapy (GDMT) 1

Heart Failure with Mildly Reduced EF (HFmrEF, LVEF 41-49%)

Moderate recommendation (Class 2a) 2:

  • SGLT2 inhibitors decrease HF hospitalizations and CV mortality
  • Particularly beneficial for patients with LVEF on lower end of spectrum

Heart Failure with Preserved EF (HFpEF, LVEF ≥50%)

Moderate recommendation (Class 2a) 2, 3:

  • Empagliflozin demonstrated reduction in composite CV death or HF hospitalization (HR 0.79) 3
  • Driven primarily by reduction in first HF hospitalization (HR 0.71)

Renal Function Considerations

Initiation Thresholds

  • Start if eGFR ≥20 mL/min/1.73 m² for most patients 4
  • Strong recommendation if eGFR ≥20 AND urine albumin-to-creatinine ratio ≥200 mg/g 4
  • Consider use even with eGFR 20-45 and lower albuminuria (weaker evidence) 4

Continuation During Renal Decline

  • Continue SGLT2 inhibitor even if eGFR falls below 20 mL/min/1.73 m² once initiated, unless not tolerated or dialysis started 4
  • Expect reversible eGFR decline of 3-5 mL/min/1.73 m² in first 4 weeks—this is not an indication to stop 4
  • Do not increase monitoring frequency due to this expected "eGFR dip" 4

Dialysis

  • Discontinue when dialysis initiated (limited efficacy data) 4
  • Exception: Dapagliflozin FDA label no longer requires discontinuation at dialysis initiation based on safety review, though efficacy uncertain 4

Practical Implementation Algorithm

Step 1: Confirm Eligibility

✓ Heart failure diagnosis (any LVEF)
✓ eGFR ≥20 mL/min/1.73 m²
✓ Not type 1 diabetes
✓ Not on dialysis

Step 2: Initiate Therapy

  • Dapagliflozin 10 mg once daily OR Empagliflozin 10 mg once daily
  • No titration required
  • Can start simultaneously with other GDMT—do not delay 1

Step 3: Adjust Concomitant Medications

  • Reduce insulin or sulfonylureas if eGFR >45 to prevent hypoglycemia 4
  • Consider reducing loop diuretic dose by 30-50% if patient euvolemic and at risk for volume depletion 1, 3
  • SGLT2 inhibitors reduce hyperkalemia risk—facilitates use of MRAs and RAS inhibitors 4

Step 4: Patient Education on "Sick Day Rules"

Withhold SGLT2 inhibitor during 4:

  • Prolonged fasting or surgery
  • Critical medical illness
  • Acute illness with nausea, vomiting, diarrhea
  • Any condition increasing ketoacidosis risk

Resume once acute illness resolves.

Safety Profile and Side Effect Management

Common Adverse Effects

Genital Mycotic Infections (10-15% in women) 1:

  • Highest risk: women, uncircumcised men, prior infection history
  • Management: topical antifungals—do not discontinue SGLT2 inhibitor
  • Prevention: daily hygiene counseling, keep genital area clean and dry 4

Urinary Tract Infections 4:

  • Treat with standard antibiotics
  • Continue SGLT2 inhibitor unless severe/recurrent

Rare but Serious Complications

Euglycemic Diabetic Ketoacidosis 1, 4:

  • Risk mitigation: implement "STOP DKA" protocol
  • Stop SGLT2 inhibitor during acute illness
  • Test for ketones if symptomatic
  • Maintain fluid and carbohydrate intake

Fournier's Gangrene 5:

  • Extremely rare
  • Permanent discontinuation required

Volume Depletion/Hypotension 1, 4:

  • Monitor in patients on high-dose diuretics
  • Reduce diuretic dose if occurs
  • Not a contraindication—adjust concomitant therapy

When to Permanently Discontinue

  • Type 1 diabetes diagnosis
  • Recurrent severe genital infections despite treatment
  • Life-threatening complications (Fournier's gangrene, urosepsis)
  • Persistent eGFR <20 after acute illness resolves (though continuation reasonable per recent data) 4

Contraindications

Absolute 1:

  • Type 1 diabetes
  • Active dialysis (relative—see above)

Relative caution (not contraindications):

  • eGFR <20 mL/min/1.73 m² (limited data for initiation, but can continue if already on therapy)
  • History of recurrent genital infections (manage proactively, not contraindication)

Monitoring

No special monitoring required beyond standard HF care 4:

  • Check eGFR and electrolytes at baseline
  • Recheck in 2-4 weeks (expect 3-5 mL/min decline—do not stop)
  • Continue routine HF monitoring thereafter
  • Monitor potassium if on MRA or RAS inhibitor

Key Clinical Pearls

The evidence is strongest for early initiation: Landmark trials (DAPA-HF, EMPEROR-Reduced) showed benefits within 30 days of starting therapy 1. The 2021 Canadian guidelines explicitly state it is "reasonable to start this class of therapy early in the disease course" rather than waiting for maximally tolerated GDMT 1.

SGLT2 inhibitors facilitate optimization of other GDMT: By reducing hyperkalemia risk and fluid retention, they enable better tolerance of MRAs, RAS inhibitors, and endothelin antagonists 4.

The "eGFR dip" is expected and protective: The initial 3-5 mL/min decline represents hemodynamic adjustment and predicts long-term kidney protection—it is not acute kidney injury 4.

Benefits are independent of diabetes status: Subgroup analyses from DAPA-HF showed nearly identical hazard ratios in diabetic (HR 0.75) versus non-diabetic patients (HR 0.73) 6.

Related Questions

Can spironolactone and a sodium‑glucose co‑transporter‑2 (SGLT‑2) inhibitor be initiated in a patient with heart failure with reduced ejection fraction who has loose bowel movements and moderate dehydration that is currently being corrected?
Which sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor should be used as first‑line therapy for patients with heart failure with reduced ejection fraction?
In a non-diabetic patient with heart failure taking Farxiga (dapagliflozin), is daily blood glucose monitoring required?
Can an SGLT‑2 inhibitor be initiated in a patient with heart failure with reduced ejection fraction and chronic liver disease who has an estimated glomerular filtration rate of 25 mL/min and a serum bicarbonate of 15 mEq/L?
What diabetes medications are safe for a patient with heart failure and chronic kidney disease, aside from sodium‑glucose cotransporter‑2 (SGLT2) inhibitors?
Can you explain the chest CT findings of a 69‑year‑old female that demonstrate progression of fibrotic interstitial lung disease with a probable usual interstitial pneumonia (UIP) pattern?
What are the recommended guidelines for correcting hypokalemia with potassium chloride in neonates, including indications, dosing, infusion rates, and monitoring?
What are the differential diagnoses for a 72‑year‑old male presenting with 15 days of watery diarrhea (~7 stools per day), fever of 38.3 °C, chills, a non‑blanching violaceous maculopapular lesion (~10 cm) on the anteromedial left leg, dark urine, hypotension (97/56 mm Hg), and a history of gout and chronic heart failure with reduced ejection fraction treated with dapagliflozin, sacubitril/valsartan, bisoprolol, and spironolactone?
Is a white blood cell count of 15.5 ×10⁹/L concerning in a patient on ipratropium/albuterol (DuoNeb) and lorazepam (Ativan)?
Is oral minoxidil 2.5 mg recommended for treating androgenic alopecia in adults?
Does discontinuing latuda (lurasidone) cause an elevated white blood cell count?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.